| 產品名稱 |
Human herpesvirus 3 |
| 商品貨號 |
B231225 |
| Classification |
Herpesviridae, Varicellovirus |
| Deposited As |
Varicella-Zoster |
| Agent |
Human herpesvirus 3 |
| Strain |
Ellen |
| Common Name |
Varicella zoster virus |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Storage Conditions |
Liquid nitrogen vapor phase |
| Comments |
VR-1367™ is a mycoplasma-free item derived at ATCC® from VR-586™ by three passages in the presence of a mycoplasma removal agent. |
| Effect on Host |
CPE, syncytial rounding and sloughing |
| Recommended Host |
MRC-5 (ATCC® CCL-171™) |
| Growth Conditions |
Temperature: 36°C
Recommendations For Infection: This product is produced by co-cultivation of virus with fresh host cells. Seed culture vessels at 1 x 105 cells per cm2. Calculate the volume of virus needed to achieve an optimal MOI (e.g. 0.01) and then dilute virus in virus growth medium to prepare the virus inoculum. Add virus inoculum to culture vessels. Incubate for 24 hours at 36°C in a humidified 5% CO2 atmosphere. Aspirate virus growth medium to remove any traces of DMSO and then add fresh virus growth medium to cultures. Continue incubation.
Incubation: 4-7 days
|
| Name of Depositor |
EI Rosanoff, Wyeth Laboratories, Inc. |
| Special Collection |
NCRR Contract |
| Source |
Vesicular fluid from child with chickenpox, Georgia. Derived from VR-586™. Treated to remove Mycoplasma hominis at ATCC®. |
| References |
Brunell PA, Casey HL. Crude tissue culture antigen for determination of Varicella-Zoster complement fixing antibody. Public Health Rep. 79: 839-842, 1964. PubMed: 14213793
Brunell PA. Transmission of chickenpox in a school setting prior to the observed exanthem. Am. J. Dis. Child. 143: 1451-1452, 1989. PubMed: 2556025
|
